

1 / 3 3




Fig. 1

BEST AVAILABLE COPY

2 / 3 3




Fig. 2

3 / 3 3




Fig. 3

4 / 3 3





Fig. 4

5 / 3 3




Fig. 5

6 / 33




Fig. 6




Fig. 7

7 / 33




Fig. 8




Fig. 9

8 / 33




Fig. 10




Fig. 11





Fig. 12

10 / 33

(2) Suppressive effect on proliferation
of Hodgkin cells – Concentration
dependence



(1) Suppressive effect on proliferation
of Hodgkin cell lines – Time-course
analysis





Fig. 13

11 / 33

(2) Concentration dependence of proliferation-suppressive effect



(1) Proliferation-suppressive effect




Fig. 14

1 2 / 3 3




Fig. 15

13 / 33




Fig. 16

1 4 / 3 3




Fig. 17

15 / 33




Fig. 18

16 / 33




Fig. 19

17 / 33




Fig. 20

18 / 33




Fig. 21




Fig. 22

20 / 33




Fig. 23

21/33




Fig. 24




Fig. 25

2 3 / 3 3

	group 1	group 2	group 3	group 4	
	Tumor (-) No administration	Tumor (+) DHMEQ i.p.	Tumor (+) DMSO i.p.	Tumor (+) No administration	* p value for Group 4
Liver (mg)	1889.9 ±44.1	*1709.5 ±81.3	1593.6 ±84.2	1262.3 ±36.2	0.9362
Spleen (mg)	109.2 ±6.4	*275.9 ±22.2	354.2 ±40.9	241.2 ±35.1	0.0691
Kidney (mg)	562.9 ±16.8	*460.3 ±22.5	423.7 ±20.1	338.1 ±9.3	0.9818
Testis (mg)	212.4 ±9.0	*203.2 ±8.2	153.0 ±9.7	127.8 ±5.9	< 0.0001
Lungs (mg)	204.6 ±7.7	*204.6 ±13.8	189.5 ±10.8	156.8 ±2.9	0.3050
Heart (mg)	163.3 ±4.5	*144.7 ±4.3	127.9 ±4.0	114.4 ±2.3	< 0.0001
Tumor (g)		*3.2 ±0.6	4.2 ±0.8	4.1 ±1.1	0.4027

Fig. 26




Fig. 27

25 / 33





Fig. 28

26 / 33

A



B




Fig. 29

27/33




Fig. 30

28 / 33




Fig. 31

29 / 33




Fig. 32

30 / 33





Fig. 33

3 1 / 3 3




Fig. 34

3 2 / 3 3




Fig. 35

33 / 33




Fig. 36

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.